RHHBF Overview
Upcoming Projects (RHHBF)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (RHHBF)
-
Discussing Roche Genentech's topline results from the Phase III REGENCY study of Gazyva® (obinutuzumab) in people with active lupus nephritis.
Ticker: RHHBF
Executed On: Nov 06, 2024 at 11:05 AM EST -
Looking at the recent Phase 3 results on Scholar Rock's apitegromab for Spinal Muscular Atrophy
Tickers: SRRK, RHHBF, BHVN, BIIB
Executed On: Oct 10, 2024 at 03:00 PM EDT -
A Second Look: A physician's impression of the Modius sleep device, a non-invasive insomnia-treating device from Neurovalens.
Tickers: NEUROVALENS, RHHBF, PFE
Executed On: Nov 13, 2023 at 03:00 PM EST -
A physician's impression of the Modius sleep device, a non-invasive insomnia-treating device from Neurovalens.
Tickers: NEUROVALENS, RHHBF, PFE
Executed On: Nov 10, 2023 at 04:00 PM EST -
Evaluating the potential of the new, higher dose version of Eylea in treating Macular Edema
Tickers: REGN, RHHBF
Executed On: Sep 29, 2022 at 03:00 PM EDT -
A Conversation on the Chronic Urticaria Landscape
Tickers: CLDX, NVS, RHHBF
Executed On: Jan 04, 2022 at 12:00 PM EST
Upcoming & Overdue Catalysts (RHHBF)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RHHBF)
-
Roche (RHHBY) presents data at ASH 2021 for novel cancer immunotherapy mosunetuzumab
Ticker: RHHBF
Occurred on: Dec 11, 2021
Strategic Initiatives (RHHBF)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
